Inhibrx Reports 62.7% ORR for Ozekibart in Ewing Sarcoma
Inhibrx announced favorable clinical data for the ozekibart combination in relapsed/refractory Ewing sarcoma, potentially offering a significant treatment advance over standard of care, while also moving its chondrosarcoma SBLA forward.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed